Skip to main content
. 2003 Oct 8;23(27):9107–9115. doi: 10.1523/JNEUROSCI.23-27-09107.2003

Figure 6.

Figure 6.

The effect of the serotonin reuptake inhibitor fluvoxamine (5 mg/kg) on motor activity (a), motor disability (b), chorea (c), dystonia (d), and dyskinesia (e) in l-DOPA-primed common marmosets treated with a combination of l-DOPA/carbidopa (12.5 mg/kg) and MDMA (12 mg/kg). Treatment with fluvoxamine in the presence of l-DOPA and MDMA blocked the inhibitory effect of MDMA on locomotor activity and dyskinesia [chorea (c); dystonia (d)] but failed to affect the effect of l-DOPA in improving motor disability (b).